OMT-28 is under clinical development by OMEICOS Therapeutics and currently in Phase II for Cardiovascular Inflammation. According to GlobalData, Phase II drugs for Cardiovascular Inflammation have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OMT-28’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OMT-28 overview

OMT-28 is under development for the treatment of wet age related macular degeneration, inflammatory risk in CAD, cardiomyopathy associated with rare mitochondrial diseases such as MELAS, Friedreich’s ataxia, Duchenne muscular dystrophy and primary Mitochondrial Disease (PMD). It is administered through oral route. The drug candidate is a synthetic small molecule analogue of the natural omega-3 fatty acid metabolite 17,18-epoxyeicosatetraenoic acid. The drug candidate acts by targeting AMPK/Sirt-1/PGC1- alpha.

It was also under development for paroxysmal and persistent atrial fibrillation, myocardial infarction, ventricular arrhythmia, macular edema diseases, and kidney injury.

OMEICOS Therapeutics overview

OMEICOS Therapeutics (OMEICOS) is a biopharmaceutical company that develops small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. It utilizes its proprietary technology of the body’s own omega-3 fatty acid metabolic processes to develop therapeutics. Its clinical product portfolio includes OMT-28, OMT 174 and OMT-224 ISA a synthetic small molecule analog of the omega-3 fatty acid metabolite 17, 18-EEQ which is developed for the treatment of paroxysmal and persistent atrial fibrillation, ventricular arrhythmia, myocardial infarction, macular edema diseases and kidney injury. The company also conducts research and development. OMEICOS is headquartered in Berlin, Germany.

For a complete picture of OMT-28’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.